New clinical trials for nonmotor manifestations of Parkinson's disease

Movement Disorders

Volumn 30, Issue 11, 2015, Pages 1490-1504

  Schrag, Anette ^a   Sauerbier, Anna ^b,c   Chaudhuri, Kallol Ray ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anxiety; Autonomic dysfunction; Depression; Fatigue; Non motor symptoms; Pain; Parkinson's disease; Psychosis; Sleep; Trial

Indexed keywords

DOXEPIN; DROXIDOPA; NARCOTIC ANALGESIC AGENT; PIMAVANSERIN; PIRIBEDIL; RIVASTIGMINE; SOLIFENACIN; NEUROLEPTIC AGENT;

ANXIETY; APATHY; AUTONOMIC DYSFUNCTION; BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; DEPRESSION; FATIGUE; HUMAN; INSOMNIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PAIN; PARKINSON DISEASE; PATIENT; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SYMPTOMATOLOGY; TRANSCUTANEOUS NERVE STIMULATION; URINARY DYSFUNCTION; COMPLICATION; HYPOTENSION, ORTHOSTATIC; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; DEEP BRAIN STIMULATION; HUMANS; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941564260     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26415     Document Type: Review

References (102)

1. Sauerbier A, Ray Chaudhuri K Non-motor symptoms: the core of multi-morbid Parkinson's disease. Br J Hosp Med (Lond) 2014;75:18-24.
2. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
3. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006;248:151-157.
4. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
5. Pavy-Le Traon A, Amarenco G, Duerr S, et al. The Movement Disorders Task Force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26:1985-1992.
6. Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord 2009;24:813-818.
7. Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014;29:1035-1043.
8. Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord 2015;21:287-291.
9. Ray Chaudhuri K, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 2013;8:e57221.
10. Martínez-Martín P, Rodríguez-Blázquez C, Mario Alvarez, et al. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord 2015;21:50-54.
11. Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol 2014;14:310-322.
12. Levin J, Hasan A, Höglinger GU. Psychosis in Parkinson's disease: identification, prevention and treatment. J Neural Transm 2015 Apr 18. [Epub ahead of print]
13. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26:S42-S80.
14. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson's disease. Ther Adv Neurol Disord 2010;3:339-350.
15. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011;68:899-904.
16. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet 2014;383:533-540.
17. Sawada H, Oeda T. Protocol for a randomized controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP). BMJ Open 2013;3:e003533.
18. Lertxundi U, Ruiz AI, Aspiazu MÁ, et al. Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish Pharmacovigilance Database. Clin Neuropharmacol 2015;38:69-84.
19. Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000Res 2013;2:150.
20. Godschalx-Dekker JA, Siegers HP. Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry 2014;47:81-83.
21. Nishioka K, Tanaka R, Shimura H, et al. Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms. J Neural Transm 2014;121:1405-1410.
22. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
23. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol 2013;27:417-423.
24. Gokbayrak NS, Piryatinsky I, Gavett RA, Ahmed OJ. Mixed effects of deep brain stimulation on depressive symptomatology in Parkinson's disease: a review of randomized clinical trials. Front Neurol 2014;5:154.
25. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-931.
26. Smith KM, Eyal E, Weintraub D. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72:88-95.
27. Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. Eur J Neurol 2015 May 12. [Epub ahead of print]
28. Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013:19:660-665.
29. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's Disease. Mov Disord 2015;30:510-516.
30. Moonen AJ, Wijers A, Leentjens AF, et al. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Parkinsonism Relat Disord 2014;20:644-646.
31. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-1074.
32. Dobkin RD, Troster AI, Rubino JT, et al. Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2014;26:57-63.
33. Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease. BMC Psychiatry 2014;14:19.
34. Lawson RA, Millar D, Brown RG, Burn DJ. Guided self-help for the management of worry in Parkinson's disease: a pilot study. J Parkinsons Dis. 2013;3:61-68.
35. Gage H, Grainger L, Ting S, et al. Specialist rehabilitation for people with Parkinson's disease in the community: a randomized controlled trial. Southampton, UK: NIHR Journals Library; 2014.
36. van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord 2013;28:605-611.
37. Chen FP, Chang CM, Shiu JH, et al. A clinical study of integrating acupuncture and Western medicine in treating patients with Parkinson's disease. Am J Chin Med 2015;43:407-423.
38. Liu Y, Li W, Tan C, et al. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease. J Neurosurg 2014;121:709-718.
39. Dashtipour K, Johnson E, Kani C, et al. Effect of exercise on motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis 2015;2015:586378.
40. Lageman S, Cash T, Mickens M. A-51. Preliminary outcome data of a clinical trial comparing a neurocognitive intervention to supportive therapy in Individuals with Parkinson's disease. Arch Clin Neuropsychol 2014;29:522.
41. Uc EY, Doerschug KC, Magnotta V, et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 2014;83:413-425.
42. den Brok MG, Dalen JW, van Gool WA, Moll van Charante EP, de Bie RM, Richard E. Apathy in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2015 Mar 18. doi: 10.1002/mds.26208. [Epub ahead of print]
43. Lewis CJ, Maier F, Eggers C, et al. Parkinson's disease patients with subthalamic stimulation and carers judge quality of life differently. Parkinsonism Relat Disord 2014;20:514-519.
44. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014;82:300-307.
45. Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013;19:660-665.
46. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-1127.
47. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013;136:1568-1577.
48. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomized clinical trial. J Neurol Neurosurg Psychiatry 2014;85:668-674.
49. Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson's disease: controversies and future approaches. Mov Disord 2015;30:150-159.
50. Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014 26;83:826-833.
51. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-658.
52. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-99.
53. Zibetti M, Rizzone M, Merola A, et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand 2013;127:e28-e32.
54. Pagonabarraga J, Piñol G, Cardozo, et al. Transdermal rotigotine improves sleep fragmentation in Parkinson's disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis 2015;2015:131508.
55. Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011;1:197-203.
56. Merlino G, Lettieri C, Mondani M, et al. Microsubthalamotomy improves sleep in patients affected by advanced Parkinson's disease. Sleep Med 2014;15:637-641.
57. Viallet F, Pitel S, Lancrenon S, Blin O. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Curr Med Res Opin 2013;29:23-31.
58. Eggert K, Öhlwein C, Kassubek J, et al. In Cooperation with the German Competence Network on Parkinson's Disease. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014;37:116-122.
59. University of Zurich. Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease (PD-Xyrem). Available from: https://clinicaltrials.gov/ct2/show/study/NCT02111122?term=oxybate+parkinson&rank=1. Accessed May 17, 2015.
60. Neikrug AB, Liu L, Avanzino JA, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep 2014;37:177-185.
61. Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease-a randomized study. Parkinsonism Relat Disord 2013;19:670-675.
62. Srinivasan V, Cardinali DP, Srinivasan US, et al. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 2011;4:297-317.
63. Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 2013;19:153-157.
64. Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther 2014:39:564-566.
65. Nomura T, Kawase S, Watanabe Y, Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med 2013;52:2123-2126.
66. Wu CK, Hohler AD. Management of orthostatic hypotension in patients with Parkinson's disease. Pract Neurol 2015;15:100-104.
67. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83:328-335.
68. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord 2015;30:646-654.
69. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H; Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive todroxidopa. Hypertension 2015;65:101-107.
70. Philadelphia Veterans Affairs Medical Center. Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine. Available from: https://clinicaltrials.gov/ct2/show/NCT02365012. Accessed May 17, 2015.
71. University of Zurich. Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease-Treatment. Available from: https://clinicaltrials.gov/ct2/show/NCT01993680. Accessed May 17, 2015.
72. Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat Disord 2015;21:514-520.
73. Perissinotto MC, D'Ancona CA, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Continence Nurs 2015;42:94-99.
74. Sir Mortimer B. Davis - Jewish General Hospital. Fesoterodine on Urgency Episodes in Parkinson's Disease Population. Available from: https://clinicaltrials.gov/ct2/show/NCT02385500. Accessed May 17, 2015.
75. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14:57-64.
76. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
77. Woitalla D, Kassubek J, Timmermann L, et al. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord. 2015;21:199-204.
78. Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78:1650-1654.
79. Rothstein RD, Friedenberg FK. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation. Expert Opin Pharmacother 2013;14:2125-2132.
80. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and welltolerated in single doses. Dig Dis Sci 2013;58:2580-2586.
81. Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39:239-253.
82. Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013;22:277-284.
83. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson's disease. Expert Opin Pharmacother 2015;16:547-557.
84. Rhythm Pharmaceuticals, Inc. A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation (MOVE-PD) Available from: https://clinicaltrials.gov/ct2/show/NCT01955616?term=NCT01955616&rank=1. Accessed May 17, 2015.
85. Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol 2014;14:42.
86. Marques A, Chassin O, Morand D, et al. Central pain modulation after subthalamic nucleus stimulation: a crossover randomized trial. Neurology 2013;81:633-640.
87. UCB BIOSCIENCES GmbH. Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain (DOLORES). Available from: https://clinicaltrials.gov/ct2/show/study/NCT01744496?term=dolores+parkinson&rank=2. Accessed May 17, 2015.
88. https://clinicaltrials.gov/ct2/show/NCT01606670?term=neupad+parkinson&rank=1. Accessed May 17, 2015.
89. Rambam Health Care Campus. Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01865097. Accessed May 21, 2015.
90. Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. J Neurol 2015 July 2. [Epub ahead of print]
91. Mundipharma Research GmbH & Co KG. A randomized placebo controlled study of OXN PR for severe Parkinson's disease associated pain. Available at: www.clinicaltrials.gov/ct2/show/NCT01439100. Accessed May 17, 2015.
92. Trenkwalder C, Martinez-Martin P, Rascol O, et al. Prolonged-release oxycodone/naloxone (OXN PR) is associated with treatment benefits in patients with severe Parkinson's disease (PD)-related pain: Results from a randomised, controlled trial [abstract]. Mov Disord 2015;30:335.
93. Ray Chaudhuri K. ABSTRACT MDS.
94. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010;133:3434-3443.
95. Haq IZ, Naidu Y, Reddy P, Chaudhuri KR. Narcolepsy in Parkinson's disease. Expert Rev Neurother 2010;10:879-884.
96. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14:57-64.
97. Pavy-Le Traon A, Amarenco G, Duerr S, et al. The Movement Disorders Task Force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26:1985-1992.
98. Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One 2013;8:e70244
99. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015;30:229-237.
100. Zis P, Martinez-Martin P, Sauerbier A, et al. Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. Eur J Neurol 2015;22:1145-1150.
101. Zis P, Erro R, Walton CC, Sauerbier A, Ray Chaudhuri K. The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 2015;1:15013. doi: 10.1038/npjparkd.2015.13.
102. Martínez-Martín P, Rodríguez-Blázquez C, Alvarez MM, et al. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2015;21:50-4.